-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2866 Ironomycin Induces Mantle Cell Lymphoma Cell Death By Targeting Iron Metabolism Addiction

Program: Oral and Poster Abstracts
Session: 622. Lymphomas: Translational–Non-Genetic: Poster II
Hematology Disease Topics & Pathways:
Lymphomas, B Cell lymphoma, Diseases, Lymphoid Malignancies
Sunday, December 11, 2022, 6:00 PM-8:00 PM

Sara ovejero-Merino, PhD1,2*, Laura Alibert3*, Julie Devin, PharmD4,5*, Tatiana Cañeque6*, Ouissem Karmous Gadacha1,2*, Matthieu Abouladze1,2*, Guilhem Requirand2*, Nicolas Robert2*, Hugues De Boussac, PhD7*, Guillaume Cartron, MD, PhD8,9*, Charles Herbaux10,11,12, Raphael Rodriguez6*, Jerome Moreaux, PhD2,5,13,14 and Caroline Bret, PhD, PharmD5,15,16*

1Institute of Human Genetics, Montpellier, FRA
2Laboratory for Monitoring Innovative Therapies, Department of Biological Hematology, CHU Montpellier, Montpellier, France
3Institute of human genetics, Montpellier, France
4CHU Montpellier, Laboratory for Monitoring Innovative Therapies, Department of Biological Hematology, Montpellier, France
5Institute of Human Genetics, UMR 9002 CNRS-UM, Montpellier, France
6Institut Curie, Paris, France
7Diag2Tec, Prades Le Lez, France
8Département d'Hématologie clinique, CHU de Montpellier, Montpellier, France
9Department of Clinical Hematology, University Hospital of Montpellier, Montpellier, France
10Hematology Department, Montpellier University Hospital, Montpellier, France, Montpellier, France
11University of Montpellier, Paris, France
12University of Montpellier, Montpellier, France
13UFR Médecine, Université Montpellier, Montpellier, France
14Institut Universitaire de France, Paris, France
15Department of Biological Hematology, CHU Montpellier, Montpellier, France
16University of Montpellier, UFR Medecine, Montpellier, France

Mantle-cell lymphoma (MCL) accounts for approximately 5 to 7% of all lymphomas, and in North America and Europe. MCL remains an aggressive and incurable cancer with existing therapies, presenting a significant unmet clinical need. Accumulating evidence reveals that abnormal iron metabolism plays an important role in tumorigenesis and in cancer progression of many tumors. In cancer cells, the demand for iron increases in response to sustained deregulation of cell proliferation and DNA synthesis. Based on these data, we searched to identify alterations of iron homeostasis in MCL that could be exploited to develop novel therapeutic strategies.

Analysis of the iron metabolism gene expression profile of a cohort of patients with MCL (n=71) established the iron score (IS), a gene expression–based risk score enabling identification of patients with MCL with a poor outcome who might benefit from a suitable targeted therapy.

We analyzed the therapeutic interest of ironomycin, a new promising iron depleting molecule. Ironomycin is known to sequester iron in the lysosome and to induce ferroptosis (Mai TT et al. Nature Chemistry 2017). Preclinical studies in Acute Myeloid Leukemia (Garciaz et al., 2022 Cancer Discovery) and Diffuse Large B-Cell Lymphoma (Devin et al., 2022 Can Res) have revealed the therapeutic interest of ironomycin in treating hematological malignancies. In a panel of 6 MCL cell lines, ironomycin inhibited MCL cell growth at nanomolar concentrations compared with typical iron chelators. Then, we investigated if ironomycin induces cell death through apoptosis. Flow cytometry analysis revealed that ironomycin treatment resulted in AnnV+/7AAD+ and AnnV+/7AAD- death profiles in MCL. This effect was partially inhibited by the pan-caspase inhibitor Q-VD-Oph. Ironomycin also induced caspases 8 and 9 cleavage, and the activation of caspases 3/7.

Furthermore, we found that ironomycin induces ferroptosis with lipid peroxidation and the production of ROS monitored by the fluorescence probe CM-H2DCFDA. Ironomycin induced cell death is inhibited by the ferroptosis inhibitor, ferrostatin-1. The treatment did not induce ferritinophagy, as there was no significant change on the expression of LC3B-II, ferritin and the transferrin receptor (CD71).Taken together, these data indicate that ironomycin kills MCL cells by apoptosis mediated by caspase activation and ferroptosis.

Ironomycin significantly decreased cell proliferation rate, with a reduced percentage of cells in S-phase together with Ki67 and Cyclin D1 downregulation. Western blot analysis showed an increase of Chk1 and Chk2 phosphorylation, two central factors of DNA damage response, and an increase of the phosphorylation of γ-H2AX, indicative of DNA damage.

With major importance, we validated the therapeutic interest of ironomycin in primary MCL cells of patients (n=5). Ironomycin (20 nM) demonstrated a significant higher toxicity in MCL cells compared to normal cells from the microenvironment. Furthermore, ironomycin presented a low toxicity on hematopoietic progenitors (CFU assays, n=5) compared to conventional treatment. We tested the therapeutic interest to combine ironomycin with conventional chemotherapy used in MCL. Interestingly, we identified a synergistic effect when ironomycin is combined with Ibrutinib BTK inhibitor. Furthermore, Significant synergistic effects were also observed by combining ironomycin with BH3 mimetics or Doxorubicin.

Altogether, these data underline that MCL patients my benefit from targeting iron homeostasis using ironomycin alone or in combination with conventional MCL treatments.

Disclosures: Cartron: MabQi, Ownards Therapeutics, Abbvie, Roche, Bristol Myers Squibb: Membership on an entity's Board of Directors or advisory committees; Gilead, Novartis, Mylteni, Sanofi, Abbvie, Takeda, Roche, Janssen, Celgene, Novartis, Bristol Myers Squibb: Honoraria. Herbaux: Abbvie: Honoraria, Research Funding; Kite: Honoraria; Roche: Honoraria; Janssen: Honoraria; Gilead: Honoraria; MSD: Research Funding; Takeda: Honoraria, Research Funding.

*signifies non-member of ASH